Achieve Life Sciences Inc. (QUIT)
NASDAQ: QUITHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QUIT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $573.25M
- EPS (TTM)
- -$1.71
- Dividend yield
- None
- 52-week range
- 2.62 – 8.64
- Day range
- 5.50 – 5.97
- Volume / Avg
- 1.92M / 1.38M
- Beta
- —
- Shares outstanding
- 103.10M
- Next earnings
- Nov 26, 2026
52-week range
QUIT stock today
On Nov 20, QUIT ended the session at $5.56, shedding $0.31 (5.28%), versus the S&P 500's 3.70% decline. Shares are 35.6% below their 52-week high of $8.64, set on Sep 3, 2026 and 112.2% above the 52-week low of $2.62, in the middle of the past year's range. Achieve Life Sciences has posted a net loss over the last twelve months (EPS of -$1.71), so its P/E ratio is not meaningful.
The company is scheduled to report Sep/2026 results on Nov 26; analysts expect EPS of -$0.19.
Summary generated from market data by MetaCap's automated system. Methodology
About Achieve Life Sciences
Company profileAchieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Andrew D. Goldberg M.D.
- Headquarters
- Bothell, WA
- Employees
- 28
- Website
- achievelifesciences.com
Financial highlights
Full financialsAchieve Life Sciences reported a net loss of $54.6 million, compared with a loss of $39.8 million a year earlier. Diluted earnings per share came in at -$1.25.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-54.65M | $-39.83M | $-29.82M | $-42.35M | $-33.15M |
| EPS (diluted) | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$14.58+162.23%
- Strong buy 3
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 26, 2026
- EPS estimate
- $-0.19
- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.28 vs $-0.19
- Surprise
- -47.37%
QUIT news
All QUIT newsAchieve Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs QUIT |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs QUIT |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs QUIT |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs QUIT |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs QUIT |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs QUIT |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs QUIT |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs QUIT |
Indexes, lists and sector
Achieve Life Sciences stock FAQ
What is Achieve Life Sciences's stock price today?
QUIT last traded at $5.56 as of Nov 20, 4:00 PM EST, down 5.28% on the day. Prices are delayed at least 15 minutes.
When is Achieve Life Sciences's next earnings date?
Achieve Life Sciences is expected to report earnings on Thursday, November 26, 2026. Analysts expect EPS of $-0.19.
Who is Achieve Life Sciences's CEO?
Dr. Andrew D. Goldberg M.D. is the chief executive officer of Achieve Life Sciences Inc., which has about 28 employees.
What is the QUIT 52-week high?
The 52-week high for QUIT is $8.64 and the 52-week low is $2.62. The stock is currently 35.6% below its high.